Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations

In recent years, therapeutic advances, together with new medication sequences and combinations, have improved outcomes for prostate cancer. For a long time, androgen deprivation therapy (ADT) has been the standard of care for newly diagnosed, metastatic prostate cancer, first as a standalone therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellan, Pietro, Marchioni, Michele, Castellucci, Roberto, De Francesco, Piergustavo, Iantorno, Romina, Schips, Luigi, Cindolo, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287515/
https://www.ncbi.nlm.nih.gov/pubmed/30584309
http://dx.doi.org/10.2147/TCRM.S159824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287515/
https://www.ncbi.nlm.nih.gov/pubmed/30584309
http://dx.doi.org/10.2147/TCRM.S159824

Ejemplares similares